Transforming growth factor β production is inversely correlated with severity of murine malaria infection

Journal of Experimental Medicine

Volumn 188, Issue 1, 1998, Pages 39-48

  Omer, Fakhereldin M ^a   Riley, Eleanor M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Immunomodulation; Interleukin 10; Malaria; Transforming growth factor ; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; HOST RESISTANCE; IMMUNOMODULATION; MALARIA; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; DISEASE MODELS, ANIMAL; INTERLEUKIN-10; MALARIA; MALE; MICE; MICE, INBRED BALB C; MONOCYTES; PLASMODIUM; RECOMBINANT PROTEINS; SPLEEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032490573     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.1.39     Document Type: Article

References (53)

1. van der Heyde, H.C., B. Pepper, J. Batchelder, F. Cigel, and W.P. Weidanz. 1997. The time course of selected malarial infections in cytokine-deficient mice. Exp. Parasitol. 85: 206-213.
2. Jacobs, P., D. Radzioch, and M.M. Stevenson. 1996. A Th1-associated increase in tumor necrosis factor alpha expression in the spleen correlates with resistance to blood-stage malaria in mice. Infect. Immun. 64:535-541.
3. Favre, N., B. Ryffel, G. Bordmann, and W. Rudin. 1997. The course of Plasmodium chabaudi chabaudi infections in interferon-gamma receptor-deficient mice. Parasite Immunol. 19:375-383.
4. Stevenson, M.M., M.F. Tam, S.F. Wolf, and A. Sher. 1995. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-γ and TNF-α and occurs via a nitric oxide-dependent mechanism. J. Immunol. 155:2545-2556.
5. Jacobs, P., D. Radzioch, and M.M. Stevenson. 1996. In vivo regulation of nitric oxide production by tumor necrosis factor alpha and gamma interferon, but not by interleukin-4, during blood stage malaria in mice. Infect. Immun. 64:44-49.
6. Nussler, A.K., L. Rénia, V. Pasquetto, F. Miltgen, H. Matile, and D. Mazier. 1993. In vivo induction of the nitric oxide pathway in hepatocytes after injection with irradiated malaria sporozoites, malaria parasites or adjuvants. Eur. J. Immunol. 23:882-887.
7. Shear, H.L., R. Srinavasan, T. Nolan, and C. Ng. 1989. Role of IFN-γ in lethal and nonlethal malaria in susceptible and resistant hosts. J. Immunol. 143:2038-2044.
8. de Souza, J.B., K.H. Williamson, T. Otani, and J.H.L. Play-fair. 1997. Early gamma interferon responses in lethal and nonlethal murine blood stage malaria. Infect. Immun. 65: 1593-1598.
9. Waki, S., S. Uehara, K. Kanbe, K. Ono, M. Suzuki, and H. Nariuchi. 1992. The role of T cells in pathogenesis and protective immunity to murine malaria. Immunology. 75:646-651.
10. Rudin, W., N. Favre, G. Bordmann, and B. Rvffel. 1997. Interferon-γ is essential for the development of cerebral malaria. Eur. J. Immunol. 27:810-815.
11. Kremsner, P.G., S. Neifer, M.F. Chaves, R. Rudolph, and U. Bienzle. 1992. Interferon-γ induced lethality in the late phase of Plasmodium vinckei malaria despite effective parasite clearance by chloroquine. Eur. J. Immunol. 22:2873-2878.
12. Linke, A., R. Kuhn, W. Muller, N. Honarvar, C. Li, and J. Langhorne. 1996. Plasmodium chabaudi chabaudi: differential susceptibility of gene-targeted mice deficient in IL-10 to an erythrocytic-stage infection. Exp. Parsitol. 84:253-263.
13. de Kossodo, S. and G.E. Grau. 1993. Profiles of cytokine production in relation with susceptibility to cerebral malaria. J. Immunol. 151:4811-4820.
14. Assosian, R.K., B.E. Fleurdelys, H.C. Stevenson, P.J. Miller, D.K. Madtes, E.W. Raines, R. Ross, and M.B. Sporn. 1987. Expression and secretion of type β transforming growth factor by activated human macrophages. Proc. Natl. Acad. Sci. USA. 84:6020-6024.
15. Wahl, S.M., N. McCartney-Francis, and S.E. Mergenhagen. 1989. Inflammatory and immunomodulatory roles of TGF-β. Immunol. Today. 10:258-261.
16. Espevik, T., I.S. Figari, M.R. Shalaby, G.A. Lackides, G.D. Lewis, H.M. Shepard, and M.A. Palladino, Jr. 1987. Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J. Exp. Med. 166:571-576.
17. Ding, A., C.F. Nathan, J. Grayear, R. Derynck, D.J. Stuehr, and S. Srimai. 1990. Macropahge deactivating factor and transforming growth factor-β1, -β2 and -β3 inhibit induction of macrophage nitrogen oxide synthesis by Interferon-γ. J. Immunol. 145:940-944.
18. Bellone, G., M. Aste-Amezaga, G. Trinchieri, and U. Rodeck. 1995. Regulation of NK cell functions by TGF-β1. J. Immunol. 155:1066-1073.
19. Maeda, H., H. Kuwahara, Y. Ichimura, M. Ohtsuki, S. Kurakata, and A. Shiraishi. 1995. TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J. Immunol. 155:4926-4932.
20. Maeda, H., and A. Shiraishi. 1996. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol. 156: 73-78.
21. Ferreira, A., L. Schofield, V. Enea, H. Schellekens, P. Van der Meide, W.E. Collins, R.S. Nussenzweig, and V. Nussenzweig. 1986. Inhibition of development of exoerythrocytic forms of malaria parasites by IFN-gamma. Science. 232:881-884.
22. Herrera, M., F. Rosero, S. Herrera, P. Caspers, D. Rotmann, F. Sinigaglia, and U. Certa. 1992. Protection against malaria in Aotus monkeys immunised with a recombinant blood stage antigen fused to a universal T cell epitope: correlation of serum gamma-interferon levels with protection. Infect. Immun. 60:154-158.
23. Riley, E.M., P.M. Jakobsen, S.J. Allen, J.G. Wheeler, S. Bennett, and B.M. Greenwood. 1991. Immune responses to soluble exoantigens of Plasmodium falciparum may contribute to both pathogenesis and protection in clinical malaria: evidence from a longitudinal, prospective study of semi-immune African children. Eur. J. Immunol. 21:1019-1025.
24. Mshana, R.N., J. Boulandi, N.M. Mshana, J. Mayombo, and G. Mendome. 1991. Cytokines in the pathogenesis of malaria: levels of IL-1β, IL-4, IL-6, TNF-α and IFN-γ in plasma of healthy individuals and malaria patients in a holoendemic area. J. Clin. Lab. Immunol. 34:131-139.
25. Harpaz, R., R. Edelman, S.S. Wasserman, M.M. Levine, J.R. Davis, and M.B. Sztein. 1992. Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge. J. Clin. Invest. 90:515-523.
26. Bouharoun-Tayoun, H., C. Oeuvray, F. Lunel, and P. Druilhe. 1995. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 182:409-418.
27. Rockett, K.A. M.M. Awburn, B.B. Aggarwal, W.B. Cowden, and I.A. Clark. 1992. In vivo induction of nitrite and nitrate by tumour necrosis factor, lymphotoxin and interleukin 1: possible roles in malaria. Infect. Immun. 60:3725-3730.
28. Grau, G.E., T.E. Taylor, M.E. Molyneux, J.J. Wirima, P. Vassalli, M. Hommel, and P.H. Lambert. 1989. Tumor necrosis factor and disease severity in children with falciparum malaria. N. Engl. J. Med. 320:1586-1591.
29. Kwiatkowski, D., A.V.S. Hill, I. Sambou, P. Twumasi, J. Castracane, K.R. Manogue, A. Cerami, O. Brewster, and B.M. Greenwood. 1990. TNF concentration in fatal, nonfatal cerebral and uncomplicated Plasmodium falciparum malaria. Lancet. 336:1201-1204.
30. McGuire, W., A.V.S. Hill, C.E.M. Allsopp, B.M. Greenwood, and D. Kwiatkowski. 1994. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature. 371:508-511.
31. Cox, F.E.G. 1988. Major animal models in malaria research: rodent. In Malaria: Principles and Practice of Malariology. W.H. Wernsdorfer and I. McGregor, editors. Churchill Livingstone, London. 1503-1543.
32. Stevenson, M.M., J.J. Lyanga, and E. Skamene. 1982. Murine malaria: genetic control of resistance to Plasmodium chabaudi. Infect. Immun. 38:80-88.
33. Yoelii, M., B. Hargreaves, R. Carter, and D. Walliker. 1975. Sudden increase in virulence in a strain of Plasmodium yoelii. Ann. Trop. Med. Parasitol. 69:173-178.
34. Peters, W. 1967. Chemotherapy of Plasmodium chabaudi infection in albino mice. Ann. Trop. Med. Parasitol. 61:52-56.
35. Danielpour, D., L.L. Dart, K.C. Flanders, A.B. Roberts, and M.B. Sporn. 1989. Immunodetection and quantitation of the two forms of transforming growth factor-β (TGF-β1 and TGF-β2) secreted by cells in culture. J. Cell. Physiol. 138:79-86.
36. Lucas, C., B.M. Fendly, F.R. Mukku, W.L. Wong, and M.A. Palladino. 1991. Generation of antibodies and assays for transforming growth factor β. Methods Enzymol. 198:303-336.
37. Bogdan, C., J. Paik, Y. Vodovotz, and C. Nathan. 1992. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10. J. Biol. Chem. 267:23301-23308.
38. 1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J. Immunol. 157:360-368.
39. 1. J. Immunol. 159:1404-1411.
40. Nandan, D., and N.E. Reiner. 1997. TGF-β attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action. J. Immunol. 158:1095-1101.
41. Wenisch, C., B. Parschalk, E. Narzt, S. Looareesuwan, and W. Graninger. 1995. Elevated serum levels of IL-10 and IFN-γ in patients with acute Plasmodium falciparum malaria. Clin. Immunol. Immunopathol. 74:115-117.
42. Wahlgren, M., J.S. Abrams, V. Fernandez, M. Bejarano, M. Azuma, M. Torii, M. Aikawa, and R.J. Howard. 1995. Adhesion of Plasmodium falciparum-infected erythrocytes to human cells and secretion of cytokines (IL-1-β, IL-1Rα, IL-6, IL-8, IL-10, TGF β, TNF α, G-CSF, GM-CSF). Scand. J. Immunol. 42:626-636.
43. Wenisch, C., B. Parschalk, H. Burgmann, S. Looareesuwan, and W. Graninger. 1995. Decreased serum levels of TGF-β in patients with acute Plasmodium falciparum malaria. J. Clin. Immunol. 15:69-73.
44. Ockenhouse, C.F., T. Tegoshi, Y. Maeno, C. Benjamin, M. Ho, K. Ei Khan, Y. Thway, K. Win, M. Aikawa, and R.R. Lobb. 1992. Human vascular endothelial cell adhesion receptors for Plasmodium falciparum-infected erythrocytes: roles for endothelial leukocyte adhesion molecule 1 and vascular cell adhesion molecule 1. J. Exp. Med. 176:1183-1189.
45. Berendt, A.R., D.L. Simmons, J. Tansey, C.I. Newbold, and K. Marsh. 1989. Intercellular adhesion molecule-1 is an endothelial cell adhesion receptor for Plasmodium falciparum. Nature. 341:57-59.
46. 1 knockout mice. J. Immunol. 158:5527-5535.
47. Spaccapelo, R., L. Romani, L. Tonnetti, E. Cenci, A. Mencacci, G. Del Sero, R. Tognellini, S.G. Reed, P. Puccetti, and F. Bistoni. 1995. TGF-β is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. J. Immunol. 155:1349-1360.
48. Pfister, H.W., K. Frei, B. Ottand, U. Koedel, A. Tomasz, and A. Fontana. 1992. Transforming growth factor β2 inhibits cerebrovascular changes and brain edema formation in the tumor necrosis factor α-independent early phase of experimental pneumococcal meningitis. J. Exp. Med. 176:265-268.
49. Poli, G., A.L. Kinter, J.S. Justement, P. Bressler, J.H. Kehrl, and A.S. Fauci. 1991. Transforming growth factor β suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte/macrophage lineage. J. Exp. Med. 173:589-597.
50. Webb, D.J., J. Wen, J.L. Lysiak, L. Umans, F. Van Leuven, and S.L. Gonias. 1996. Murine α-macroglobulins demonstrate divergent activities as neutralizers of transforming growth factor-β and as inducers of nitric oxide synthesis. J. Biol. Chem. 271:24982-24988.
51. Silva, J.S., D.R. Twardzik, and S.G. Reed. 1991. Regulation of Trypansoma cruzi infections in vitro and in vivo by transforming growth factor β (TGF-β). J. Exp. Med. 174:539-545.
52. Barral-Neto, M., A. Barral, C.E. Brownwell, Y.A.W. Skeiky, L.R. Ellingsworth, D.R. Twardzik, and S.G. Reed. 1992. Transforming growth factor β in leishmanial infections: a parasite escape mechanism. Science. 257:545-548.
53. Marth, T., W. Strober, R.A. Seder, and B.L. Kelsall. 1997. Regulation of transforming growth factor-β production by interleukin-12. Eur. J. Immunol. 27:1213-1220.